AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04634006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home-based transcranial direct current (tDCS) device
Description: tDCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes in order to modify the cerebral activity of the stimulated zones. Twenty sessions (active/sham) will be self-administered by parent or caregiver on twenty consecutive business days. The parameter of electrode size, current strength and current duration were previously tested for safety in children. The investigators use the Soterix Medical tDCS devices of the home-based miniCT 1x1 type.
Study NCT04634006 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Home-based transcranial direct current (tDCS) device
Description: tDCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes in order to modify the cerebral activity of the stimulated zones. Twenty sessions (active/sham) will be self-administered by parent or caregiver on twenty consecutive business days. The parameter of electrode size, current strength and current duration were previously tested for safety in children. The investigators use the Soterix Medical tDCS devices of the home-based miniCT 1x1 type.
Study NCT00828165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-300, MEK inhibitor; oral
Description: single dose, escalating
Study NCT00828165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT01088230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botox®
Description: the treatment group will receive a one time injection of Botox® at the wrist flexors and pronators of the affected arm. Each subject will receive a standard dose of 150 units total, 50u each to the flexor carpi radialis and flexor carpi ulnaris, and 25u each for the pronator teres and pronator quadratus muscle groups.
Study NCT01088230 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: the control group will receive a one time injection of salt water in the flexor carpi radialis and flexor carpi ulnaris, and the pronator teres and pronator quadratus muscle groups.
Study NCT01439256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Controlled Telephone Counseling
Description: The subjects in the intervention arm receive medication adherence counseling through a computer controlled telephone counseling program
Study NCT01439256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician information and management recommendations
Description: Treating physicians for those subjects in the intervention arm receive through the medical record system a summary of blood pressure values and adherence data and recommendations.
Study NCT03289819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w. After the 25th patient has started trial treatment, all further included patients will receive 1 cycle of pembrolizumab i.v. 200 mg q3w monotherapy followed by 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w.
Study NCT03289819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
Study NCT03289819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
Study NCT03289819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
Study NCT04065412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified laryngeal handshake technique
Description: The modified laryngeal handshake is performed with the non-dominant hand, stabilizing the trachea between thumb and middle finger from the suprasternal notch and moving up the neck to palate the cricoid cartilage and cricothyroid membrane with the index finger.
Study NCT00816543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOCETAXEL
Description: 50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.
Study NCT00816543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.
Study NCT00816543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXALIPLATIN
Description: 100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.
Study NCT00208702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triiodothyronine
Study NCT00208702 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00208702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline
Study NCT00208702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Study NCT03221803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OT Vertical attachment
Description: new extra coronal castable attachment
Study NCT04340167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous humanized anti-CD22 chimeric antigen receptor T cells
Description: CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD22 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR T-cell infusion to determine the disease status.
Study NCT03611985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiferphane
Description: During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each of the two taxane regimens (weekly paclitaxel or docetaxel every 3 weeks).~All subjects in the phase IIa portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months.
Study NCT03611985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane Chemotherapy
Description: All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
Study NCT03221803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OT cap attachment
Description: standard extra coronal attachment
Study NCT04414709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Double short implant
Description: Patients receives 2 short implants to restore missing posterior teeth, loaded with splinted screw retained crowns.
Study NCT04414709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single short implant
Description: Patients receives single short implants, loaded with single screw retained crowns.
Study NCT04361695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: The patient receives spinal anaesthesia and is placed in lithotomy position. A complex of external and internal haemorrhoid or internal haemorrhoid only is excised with monopolar electrocautery or bipolar electrosurgery device. Haemorrhoid pedicle is tied with absorbable polyfilament suture. One, two or three nodes can be removed per a procedure.
Study NCT04361695 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hemorrhoidectomy
Description: The patient receives spinal anaesthesia and is placed in lithotomy position. A complex of external and internal haemorrhoid or internal haemorrhoid only is excised with monopolar electrocautery or bipolar electrosurgery device. Haemorrhoid pedicle is tied with absorbable polyfilament suture. One, two or three nodes can be removed per a procedure.
Study NCT04361695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprophenum
Description: Ketoprophenum
Study NCT04361695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03349216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous Regional Anesthesia
Description: in this research patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes (A.T.S. 2000, Zimmer, Inc., Bloomfield, CN) will be deflated (hence named Rapid MiniBier's block). the pain score will be assessed by NRS system before during and after the procedure.
Study NCT04215159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab biosimilar
Description: 1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.
Study NCT04215159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: 1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.
Study NCT04215159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: 100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks.
Study NCT02005458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Study NCT02005458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Study NCT02005458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Study NCT02005458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Study NCT01312558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prudent diet group
Study NCT01312558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet group
Study NCT03426189 — intervention group
Intervention type: PROCEDURE
Intervention: Leukapheresis
Description: Blood will be taken by a needle inserted into a vein in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out of the machine for purposes of this research. The rest of the blood will be returned through a needle in the other arm.
Study NCT03426189 — intervention group
Intervention type: PROCEDURE
Intervention: Lymph node biopsy
Description: Ultrasound will be used to localize the position of one lymph node in the groin. Under a light general anesthetic, one lymph node will be removed.
Study NCT03524521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval Training
Description: Interval training is prescribed 3 days per week using 5 body weight exercises in a progressive fashion.
Study NCT03524521 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Walking prescribed to meet current exercise guidelines; 150 minutes per week.
Study NCT01525914 — intervention group
Intervention type: DRUG
Intervention: Dutasteride
Description: dutasteride 0.5mg daily
Study NCT05392218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: consisted of six sessions (twice each week) up to 30 minutes of individual sessions. Each session contained a different component and topic that included substance abuse, physical activity, healthy sleep, stress management, nutrition and social support. The components in order were randomized for each participant.
Study NCT00479973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamonforce
Description: Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.~2 capsules after the two largest meals of the day
Study NCT00479973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. 2 capsules after the two largest meals of the day
Study NCT01522963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task
Study NCT05392218 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: general health education
Description: rceived the same amount of virtual session equivalent to MI form. However, the structure of the sessions consisted of brief advice to promote healthy lifestyle delivered by different therapists
Study NCT02841982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-injection QLB(quadratus lumborum block)
Description: Inject local anesthetics in between quadratus lumborum and psoas major without continuous local infusion
Study NCT02841982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philip CX50 Ultrasound Scanner
Description: The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
Study NCT02307331 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optivac
Description: A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results
Study NCT02307331 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optipac
Description: A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system
Study NCT02307331 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Arcom (Exceed cup)
Description: The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene
Study NCT02307331 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: E1 (Exceed cup)
Description: The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.
Study NCT02307331 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sirius stem
Description: A polished tapered stem
Study NCT00106496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protopic
Description: topical
Study NCT00106496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: topical
Study NCT00106496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: topical
Study NCT01444989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AKRQ questionnaire
Description: The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors
Study NCT02841982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAJUNK StimuLong
Study NCT01444989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skindex-16, DLQI, Skin Health Calculator
Description: These are all previously validated questionnaires
Study NCT02841982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose ropivacaine
Description: * 0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline.~* given immediately after the correct position of the tip of the needle has been verified.
Study NCT02841982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine given as IPCA(intravenous patient controlled analgesia)
Description: bolus: 1.5\~2mg, lock time: 10min, 1h limitation: 6\~8mg
Study NCT02841982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine given as IPCA(intravenous patient controlled analgesia)
Description: bolus: 1.5\~2mg, lock time: 10min, 1h limitation: 6\~8mg
Study NCT03151174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 10000 UNT
Description: 10000 IU Vitamin D per day
Study NCT03151174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 5000 UNT
Description: 5000 IU Vitamin D per day
Study NCT04469777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
Study NCT03349216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Analgesia
Description: in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect. again here the pain score will be assessed before procedure and after the procedure every 5 minutes until 30 minutes by NRS ( Numerical Rating Score)
Study NCT00127712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Study NCT02267460 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AA4500
Study NCT02281422 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BIA 2-093
Study NCT02267460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ErecAid® Esteem® Manual Vacuum Therapy System
Study NCT04222582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
Study NCT04222582 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
Study NCT04222582 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
Study NCT02098590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPS-immunization
Description: Subjects will be exposed 3 times to bites from 15 NF54 Plasmodium infected mosquitoes during each immunization, while taking chloroquin prophylaxis.
Study NCT02098590 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CPS-immunization
Description: Subjects will be exposed 3 times to bites from 15 NF54 Plasmodium infected mosquitoes during each immunization, while taking chloroquin prophylaxis.
Study NCT02098590 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: malaria challenge infection, P. falciparum NF135.C10
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
Study NCT02098590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum NF135.C10
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.